

(1)

#16  
Statement  
3/12/03

ATTORNEY'S DOCKET NUMBER: 2002850-0009 (S98-161 US CIP II)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Fount et al.  
Serial No.: 09/728,720  
Filed: December 1, 2000  
For: PREVENTION AND TREATMENT OF HCV INFECTION EMPLOYING  
ANTIBODIES DIRECTED AGAINST CONFORMATIONAL EPITOPES

Examiner: Wortman, D.  
Art Unit: 1648

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:


TECH CENTER 1600/2900

FEB 25 2003

RECEIVED

**STATEMENT UNDER 37 CFR 1.804(b)**

I Steven Fount submit that the biological material, which is deposited with the American Type Culture Collection (10801 University Blvd., Manassas, VA 20110-2209), including mouse/human hybridoma cell lines expressing antibodies CBH-2 (ATCC no. PTA-4465), CBH-4B (ATCC no. PTA-4466), CBH-4D (ATCC no. PTA-4467), CBH-4G (ATCC no. PTA-4468), CBH-5 (ATCC no. PTA-4469), CBH-7 (ATCC no. PTA 4470), CBH-8C (ATCC no. PTA-4471), CBH-11 (ATCC no. PTA-4472) and CBH-17 (ATCC no. PTA-4473) is a biological material specifically identified in the application as filed. For example, all of the antibodies produced by the hybridomas as disclosed in Table 1 of the application on page 16, page 35, lines 14-15, and Table 3.

  
Steven Fount

Feb. 7, 2003  
Date